Core Laboratories N.V. (NYSE:CLB)‘s stock had its “hold” rating reissued by Cowen and Company in a note issued to investors on Friday. They currently have a $100.00 price objective on the oil and gas company’s stock. Cowen and Company’s price target indicates a potential upside of 13.40% from the stock’s current price.

Several other research firms have also issued reports on CLB. Piper Jaffray Companies set a $97.00 price objective on Core Laboratories N.V. and gave the company a “hold” rating in a research note on Wednesday, July 26th. Citigroup Inc. lowered their price objective on Core Laboratories N.V. from $102.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, July 26th. ValuEngine raised Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Royal Bank Of Canada set a $145.00 price objective on Core Laboratories N.V. and gave the company a “buy” rating in a research note on Saturday, June 17th. Finally, Zacks Investment Research lowered Core Laboratories N.V. from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $116.33.

Core Laboratories N.V. (NYSE:CLB) opened at 88.18 on Friday. Core Laboratories N.V. has a 52 week low of $87.17 and a 52 week high of $125.83. The firm has a 50-day moving average price of $96.83 and a 200-day moving average price of $105.93. The stock has a market capitalization of $3.89 billion, a PE ratio of 54.10 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last posted its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.01. The business had revenue of $163.90 million during the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the company earned $0.35 EPS. Equities research analysts predict that Core Laboratories N.V. will post $2.09 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/core-laboratories-n-v-s-clb-hold-rating-reiterated-at-cowen-and-company/1535369.html.

Large investors have recently modified their holdings of the company. Clearbridge Investments LLC increased its stake in shares of Core Laboratories N.V. by 3.8% in the first quarter. Clearbridge Investments LLC now owns 5,219,879 shares of the oil and gas company’s stock valued at $603,000,000 after buying an additional 190,186 shares during the last quarter. WCM Investment Management CA increased its stake in shares of Core Laboratories N.V. by 7.3% in the second quarter. WCM Investment Management CA now owns 4,433,175 shares of the oil and gas company’s stock valued at $448,948,000 after buying an additional 303,073 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Core Laboratories N.V. by 1.6% in the second quarter. Vanguard Group Inc. now owns 3,672,865 shares of the oil and gas company’s stock valued at $371,950,000 after buying an additional 56,807 shares during the last quarter. Sustainable Growth Advisers LP increased its stake in shares of Core Laboratories N.V. by 36.9% in the second quarter. Sustainable Growth Advisers LP now owns 2,345,271 shares of the oil and gas company’s stock valued at $237,505,000 after buying an additional 632,263 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Core Laboratories N.V. by 1.3% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,702,000 shares of the oil and gas company’s stock valued at $172,364,000 after buying an additional 22,276 shares during the last quarter.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.